No Data
New Digital First Marketing Campaign From Esperion Alerts Patients With Uncontrolled LDL Cholesterol to the "Lipid Lurkers" Inside Their Arteries
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk "Lurking" In Patients'
Notable Analyst Calls This Week: Nike, Micron and FedEx Among Top Picks
Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $8
Needham analyst Serge Belanger maintains $Esperion Therapeutics(ESPR.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 39.8% an
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright analyst Joseph Pantginis maintains $Esperion Therapeutics(ESPR.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate
Express News | HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
Esperion Shares Rise on Monetization of European Royalties
By Don Nico Forbes Shares in Esperion Therapeutics rose 31% in premarket trading after the company signed a purchase agreement with Omers Life Sciences concerning its Daiichi Sankyo royalties in Euro